OncoMatch/Clinical Trials/NCT07499674
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
Is NCT07499674 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Abenacianine for lung cancer.
Treatment: Abenacianine — This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Prior therapy
Cannot have received: chemotherapy
They have received chemotherapy...within 4 weeks prior to study enrollment.
Cannot have received: immunotherapy
They have received...immunotherapy...within 4 weeks prior to study enrollment.
Cannot have received: radiotherapy
They have received...radiotherapy within 4 weeks prior to study enrollment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- Orlando Health Cancer Center · Orlando, Florida
- Mayo Clinic · Rochester, Minnesota
- Hospital of the University of Pennsylvania · Philadelphia, Pennsylvania
- University of Texas, MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify